

12 Jan 2026
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2026/01/12/3216838/0/en/Cadrenal-Therapeutics-Highlights-High-Incidence-of-Thrombotic-Complications-in-Heparin-Induced-Thrombocytopenia-HIT-at-the-J-P-Morgan-Healthcare-Conference-and-VLX-1005-as-a-Potent.html

12 Dec 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/12/11/3203875/0/en/Cadrenal-Therapeutics-Acquires-VLX-1005-a-First-in-Class-Phase-2-12-LOX-Inhibitor-for-Patients-with-Heparin-Induced-Thrombocytopenia-HIT.html